Cognitive Assessment for Liver Surgery Patients

Overseen by Timothy Newhook, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial studies how well electronic neurocognitive tools work in screening for mental capability in patients who are undergoing liver surgery. Using electronic neurocognitive screening tools may help to better assess mental impairment.

Research Team

Timothy Newhook, MD

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for English-speaking patients at UT-MD Anderson Cancer Center who are about to have liver surgery and can give informed consent. It's designed to see if they're mentally sharp enough for the procedure.

Inclusion Criteria

I speak English, can make decisions about my care, and am having liver surgery at UT-MD Anderson.

Treatment Details

Interventions

• BrainCheck Cognitive Assessment (Behavioral Intervention)
• Cognitive Assessment (Procedure)

Trial Overview The study is testing electronic tools called BrainCheck Cognitive Assessment to screen mental capability in patients before liver surgery, aiming to identify any cognitive impairments more effectively.

Participant Groups

Group I: Group I (BrainCheck and paper and pen cognitive assessment) Experimental Treatment 2 Interventions

Patients receive the BrainCheck cognitive assessment over 15 minutes followed by the paper and pen assessment 2 months prior to surgery and within 2 months after surgery.

Group II: Group II (pen and paper and BrainCheck cognitive assessment) Active Control 2 Interventions

Patients receive the paper and pen assessment followed by the BrainCheck cognitive assessment over 15 minutes 2 months prior to surgery and within 2 months after surgery.

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials

3,107

Recruited

1,813,000+

Dr. Peter WT Pisters

M.D. Anderson Cancer Center

Chief Executive Officer since 2017

MD from University of Western Ontario

Dr. Jeffrey E. Lee

M.D. Anderson Cancer Center

Chief Medical Officer

MD from Stanford University School of Medicine

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Dr. Douglas R. Lowy

National Cancer Institute (NCI)

Chief Executive Officer since 2023

MD from New York University School of Medicine

Dr. Monica Bertagnolli

National Cancer Institute (NCI)

Chief Medical Officer since 2022

MD from Harvard Medical School